An Observational Study of MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in First-Line in Patients With Diffuse Large B-Cell Lymphoma

Roche

Status: Terminated

Conditions: Diffuse Large B-Cell Lymphoma

Study type: Observational

Funder types: Industry

Identifiers

NCT01724294

ML28497

Details and patient eligibility

About

This multicenter, observational study will evaluate the correlation between clinical and biological factors and International Prognostic Index (IPI) as prognostic factors in patients with diffuse large B-cell lymphoma receiving first-line treatment with MabThera/Rituxan (rituximab) in combination with CHOP chemotherapy. Eligible patients receiving treatment according to standard of care and local guidelines will be followed for the duration of treatment (approximately 8 months) and during 1 year of follow-up.

Enrollment: 113 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients, >18 years of age
• Patients with diagnosed diffuse large B-cell lymphoma in first-line treatment with R-CHOP

Exclusion criteria

• Prior chemotherapy treatment for diffuse large B-cell lymphoma
• Contra-indications or exclusion criteria according to the Summary of Product Characteristics for MabThera/Rituxan

Trial design

113 participants in 1 patient group

Cohort